Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. (Q51725420)

10 April 2018

title

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. (English)

1 reference

10 April 2018

cost-effectiveness analysis

main subject

1 reference

Ralph P Insinga

1

1 reference

10 April 2018

Erik J Dasbach

2

1 reference

10 April 2018

Elamin H Elbasha

3

1 reference

10 April 2018

Andrea Puig

4

1 reference

10 April 2018

Luz Myriam Reynales-Shigematsu

5

1 reference

10 April 2018

language of work or name

English

0 references

publication date

20 November 2007

1 reference

10 April 2018

published in

Vaccine

1 reference

10 April 2018

volume

26

1 reference

10 April 2018

issue

1

1 reference

10 April 2018

page(s)

128-139

1 reference

10 April 2018

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Genital human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Natural history of cervical intraepithelial neoplasia: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Prognostic factors related to cervical cancer survival in Mexican women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cervical cancer screening with cervicography and cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Papanicolaou smear screening augmented by a magnified chemiluminescent exam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

The health and economic burden of genital warts in a set of private health plans in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

The health care costs of cervical human papillomavirus--related disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

External genital warts: diagnosis, treatment, and prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

[Cost-effectiveness of interventions for end-stage renal disease]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Priority setting for health interventions in Mexico's System of Social Protection in Health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Overcoming economic barriers to the optimal use of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cost-effectiveness of treating multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Annual productivity costs due to cervical cancer mortality in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.056

10.1016/J.VACCINE.2007.10.056

7 January 2021

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018